Boston University

The General Hospital Corporation

Wilson Wai Chun Wong

Yage Ding

Mark W Grinstaff

Yolonda Colson

Ahmad S Khalil

Huishan Li

Eric M Bressler

Divya Israni

Sarah Adams

The technology described herein is directed to inducible and repressible polypeptides and polypeptide systems. In particular, described herein are split sequence-specific nucleases and split recombinases that are linked to drug-inducible or drug-repressible dimerization domains. In some embodiments, the polypeptides comprise sequestering domains and/or have their expression controlled by an inducible promoter. In multiple aspects described herein are polynucleotides, vectors, cells, and pharmaceutical compositions comprising said polypeptides or polypeptide systems. Also described herein are methods of using said polypeptide systems to modulate the expression of a target polypeptide or to treat a subject in need of a cell therapy.

Repressible control of gene expression

The present disclosure generally relates to compositions and method for delivery, e.g., sustained delivery of active agents, and their use for the treatment of diseases or disorders.

Nanofiber scaffolds

Inducible control of gene expression

The technology described herein is directed to regulated synthetic gene expression systems. In one aspect described herein are synthetic transcription factors (synTFs) comprising a DNA binding domain, a transcriptional effector domain, and a regulator protein. In other aspects described herein are gene expression systems comprising said synTFs and methods of treating diseases and disorders using said synTFs.

Regulated synthetic gene expression systems

Growing community of inventors

Brookline, MA, United States of America

Wilson Wai Chun Wong